Amgen acquires Dark Blue for up to $840M, gaining a protein-degrading drug targeting acute myeloid leukemia.
Browsing: M&A and Licensing
News and insights on mergers, acquisitions, licensing deals, and strategic collaborations across the global pharma industry.
BioMarin Amicus acquisition for $4.8B adds a late-stage asset and two marketed therapies generating $450M in nine months.
BioMarin Amicus acquisition valued at $4.8 billion adds a late-stage asset and two marketed therapies generating $450 million.
Xoma acquires Generation Bio, a gene therapy developer, in a strategic move to enhance its biotech portfolio.
Pfizer obesity pill China deal involves a $2 billion agreement with Fosun Pharma, aiming to enhance its weight loss medication offerings.
Mirum Bluejay acquisition secures a late-stage hepatitis D drug, enhancing its pipeline with potential $200M in additional payouts.
Contingent value rights are increasingly used in biotech deals, bridging price gaps amid market turbulence.
Contingent value rights are increasingly used in biotech deals to bridge price gaps amid market turbulence.#PharmaSignal #Biotech #MergersAndAcquisitions
Biogen Dayra partnership aims to identify oral macrocycle candidates for high-priority immunological targets, enhancing Biogen’s immune portfolio.
Purdue Pharma settlement approved, Sacklers to pay $7 billion over 15 years to address opioid crisis.